Hypercor/Hypercor 2.5

Bisoprolol fumarate

Hypercor: Essential HTN, angina pectoris, CHF. Hypercor 2.5: Monotherapy or in combination w/ other classes of antihypertensives in management of HTN.

Hypercor Essential HTN, angina pectoris 5 mg. May increase to 10 mg if not adequate. CHF Initially 1.25 mg daily for 1 wk, gradually increase to 2.5 mg daily for 1 wk then 3.75 mg daily for 1 wk then 5 mg daily for the following 4 wk & 7.5 mg daily for the following 4 wk. Maintenance: 10 mg daily. All doses to be taken once daily. Hypercor 2.5 HTN Initially 2.5-5 mg once daily. Patients w/ inadequately controlled BP w/ initial dosage Increase dose gradually w/ at least 2-wk interval. Max: 20 mg once daily. Severe hepatic or renal impairment w/ CrCl <40 mL/min Initially 2.5 mg once daily, CrCl <20 mL/min Max: 10 mg daily.

May be taken with or without food.

Cardiogenic shock, 2nd or 3rd-degree AV block, hypotension, phaeochromocytoma w/o concomitant α-blockers therapy. Hypercor: Untreated myocardial failure, sick-sinus syndrome, SA block, bradycardia (<50 beats/min), bronchial asthma, advanced stages of peripheral circulatory disturbance. Pregnancy & lactation. Childn. Hypercor 2.5: Uncontrolled heart failure or acutely decompensated heart failure requiring IV inotropic therapy, sinus bradycardia, severe peripheral arterial disease, metabolic acidosis, bronchospasm or asthma or history of obstructive airways disease.

Diabetics. Hypercor: Fluctuating blood sugar levels, during prolonged periods of fasting; acidosis. Prior operation as cardiac output may be impaired under anesth. Elderly >80 yr. Hypercor 2.5: History of severe anaphylaxis. Avoid in patients w/ Prinzmetal's angina. Not to stop treatment abruptly especially in patients w/ ischaemic heart disease. Precipitate or aggravate symptoms of arterial insufficiency in patients w/ peripheral vascular & Raynaud disease; thyroid storm w/ abrupt w/drawal. Patients w/ 1st-degree AV block; hyperthyroidism; psoriasis or w/ history of psoriasis. Monitor for progression of arterial obstruction. Pregnancy & lactation. May increase risk of adverse maternal outcomes w/ untreated chronic HTN. Monitor fetal growth during pregnancy; newborn for 48 hr after delivery for bradycardia, hypoglycemia & resp depression.

Depression, dizziness, fatigue, headache, vivid dream; diaphoresis; sleep disturbance. Hypercor: May aggravate intermittent claudication & Raynaud's phenomenon, intensify myocardial failure, increase airway resistance, mask sign of low sugar levels. Hypercor 2.5: Cardiac arrhythmia & failure, chest pain, claudication, cold extremities, edema, flushing, hypersensitivity angiitis, hypotension, orthostatic hypotension, palpitations; anxiety, drowsiness, hyper- & hypoesthesia, insomnia, lack of conc, malaise, memory impairment, paresthesia, restlessness, eye pressure sensation, twitching, vertigo; acne vulgaris, alopecia, eczema, pruritus, skin irritation & rash; decreased libido, gout, increased serum glucose, phosphate, K, triglycerides, uric acid, wt gain; abdominal pain, constipation, diarrhea, dysgeusia, dyspepsia, epigastric & gastric pain, gastritis, nausea, peptic ulcer, vomiting, xerostomia; cystitis, impotence; decreased WBC count, +ve ANA titers, purpuric rash, thrombocytopenia; increased serum ALT & AST; back & neck pain, muscle cramps, myalgia, tremor; abnormal lacrimation, eye pain, visual disturbance; otalgia, tinnitus; increased BUN, serum creatinine, polyuria, renal colic; asthma, bronchitis, bronchospasm, cough, dyspnea, dyspnea on exertion, pharyngitis, rhinitis, sinusitis, URTI; angioedema, arthralgia, asthenia, auditory impairment, bradycardia, dermatitis, exfoliative dermatitis, Peyronie disease, psoriasis, syncope, unsteadiness.

Concomitant use w/ reserpine, α-methyldopa, Ca antagonist of verapamil- & diltiazem-type, antiarrhythmics, insulin or oral blood sugar-lowering drugs. Hypercor 2.5: Increased levels/effects of α₁-blockers, α₂-agonists, amifostine, antipsychotic agents (eg, phenothiazines), 2nd generation atypical antipsychotics, bradycardia-causing agents, bromperidol, bupivacaine, cardiac glycosides, ceritinib, cholinergic agonists, disopyramide, duloxetine, ergot derivatives, fexinidazole, fingolimod, grass pollen allergen extr (5 grass extr), hypotension-associated agents, insulins, ivabradine, lacosamide, levodopa-containing products, systemic/topical lidocaine, mepivacaine, methacholine, nitroprusside, pholcodine, siponimod, sulfonylureas. Increased levels/effects w/ acetylcholinesterase inhibitors, alfuzosin, α₂-agonists, aminoquinolines (antimalarial), amiodarone, antipsychotics (eg, phenothiazines), barbiturates, benperidol, brigatinib, topical brimonidine, non-dihydropyridine Ca channel blockers, diazoxide, dipyridamole, disopyramide, dronedarone, floctafenine, herbs (hypotensive properties), lormetazepam, methoxyflurane, midodrine, molsidomine, naftopidil, nicergoline, nicorandil, nifedipine, obinutuzumab, opioids (eg, anilidopiperidine), pentoxifylline, phosphodiesterase 5 inhibitors, propafenone, prostacyclin analogues, quinagolide, regorafenib, reserpine, rivastigmine, ruxolitinib, terlipressin, tofacitinib. Decreased levels/effects of β₂-agonists, nasal/oral/inhalation/racemic/systemic epinephrine, theophylline derivatives. Decreased levels/effects w/ amphetamines, barbiturates, bosentan, brigatinib, bromperidol, moderate/strong CYP3A4 inducers, dabrafenib, deferasirox, dexmethylphenidate, enzalutamide, erdafitinib, herbs (hypertensive properties), ivosidenib, lorlatinib, methylphenidate, mitotane, NSAIDs, rifamycin derivatives, sarilumab, siltuximab, tocilizumab, yohimbine.

Beta-Blockers

C07AB07 - bisoprolol ; Belongs to the class of selective beta-blocking agents. Used in the treatment of cardiovascular diseases.

D